Exclusive Summary

• - Long off-patent globally with EU27 registrations completed; outside the US (orphan exclusivity until ~2029), most markets are open for distribution now.
• - Targets two high-need settings—acute variceal bleeding and HRS-AKI—with stable hospital demand embedded in emergency care pathways.
• - Strong guideline endorsement and WHO EML listing (first-line for AVB; HRS-AKI with albumin) with clear efficacy data.
• - Competitive but differentiated: ready-to-use 0.1 mg/ml (8.5 ml) solution reduces preparation time and medication errors versus reconstitution products.
• - EU-wide regulatory track record and quality systems, with 30–60% price reduction versus originator enabling tender and cost-containment wins.